This study used whole-genome sequencing from two large biobanks to define genetic contributors to immune cytopenia. The authors examined four distinct types of genetic variation: rare germline variants in genes implicated in inherited errors of immunity, common germline variants that mediate risk for systemic lupus erythematosus (SLE), somatic variants related to hematological malignancies, and somatic variants indicative of clonal hematopoiesis. The analyses were performed using data accessed under license from the UK Biobank and the All of Us Research Program.
The authors report that rare germline variants in genes classically linked to inherited errors of immunity contribute independently to immune cytopenia risk. In particular, carriers of variants in some autosomal recessive genes of inherited immune deficiency pathways had an increased risk of developing immune cytopenia. The study emphasizes that rare, inherited variation can be an important and distinct driver of immune cytopenia risk separate from common-variant susceptibility or somatic changes.
Common-variant genetic architecture associated with systemic lupus erythematosus also increased risk for immune cytopenia. The authors evaluated common germline variation implicated in SLE and observed that polygenic or common-variant mediated SLE risk was associated with an increased probability of immune cytopenia, indicating overlap between autoimmune genetic susceptibility and cytopenic phenotypes.
Somatic genetic changes were separately assessed and found to contribute to immune cytopenia risk. Both somatic variants associated with overt hematological malignancies and those marking clonal hematopoiesis were identified as independent risk sources. Thus, the somatic landscape—whether reflecting malignant processes or age-related clonal expansions—represents a distinct axis of genetic risk for immune cytopenia.
Across the cohorts analyzed, a substantial fraction of individuals with immune cytopenia carried at least one of the four genetic risk categories under study. The authors summarize that approximately one-third to one-half of patients with immune cytopenia harbored at least one of these genetic contributors, indicating that a large proportion of cases have an identifiable genetic signal from these examined classes.
Combining information from the four variant classes enabled stratification of immune cytopenia risk at the population level. In the general-population analysis, estimated 10-year incidence of immune cytopenia varied markedly across risk strata: the lowest-risk group had a 10-year incidence of 0.08%, whereas the highest-risk group had a 10-year incidence of 1.5%. The authors report that this combined approach permitted risk stratification both in general-population samples and in higher-risk subpopulations, demonstrating potential utility of integrated germline and somatic profiling for predicting immune cytopenia risk.
The analyses used resources from the UK Biobank and the All of Us Program under their respective access terms; the manuscript reports the UK Biobank Application Number used. Code used for the study is available from the authors’ public GitHub repository. Ethical approval was provided by the CHU Sainte-Justine ethics committee, and participant consent procedures were followed. One author disclosed receipt of a research scholarship and unrelated industry funding; the remaining authors declared no competing financial interests.
Note on scope and source information
All findings, numbers, and statements in this summary are drawn from the source preprint. Specific statistical models, effect sizes for individual variants or genes, cohort counts, and additional analytic details were not reported in full in the summary paragraphs provided here; readers should consult the full preprint and available supplementary material and code repository for complete methods and results.